Humacyte

Historical price data

Humacyte's mission is to develop and commercialize universally implantable, off-the-shelf, regenerative human tissues to treat injury and disease. Its foundational achievement is the December 2024 FDA approval of Symvess™ (acellular tissue engineered vessel-tyod) for vascular trauma repair, marking its entry into the commercial market. The company's strategy leverages its scalable Human Acellular Vessel (HAV) platform, now commercialized as the Acellular Tissue Engineered Vessel (ATEV™), to expand into large adjacent markets like arteriovenous (AV) access for hemodialysis and peripheral arterial disease (PAD). With a deep pipeline across three technology platforms, Humacyte is positioned to address multi-billion dollar markets with its first-of-its-kind regenerative products.

Proprietary Human Acellular Vessel (HAV)/Acellular Tissue Engineered Vessel (ATEV™) platform that biofabricates, decellularizes, and implants universally compatible extracellular matrix scaffolds, which are then regenerated into living tissue by the patient's own cells.